Titan Pharmaceuticals has been cleared to start the second phase of a trial of its ropinirole implant for Parkinson’s disease—but will have to postpone it because of financial constraints.
Teva earlier this week inked a pact to sell off one of its women’s health products—and now it’s closing in on a deal to divest that business’s assets outside the U.S.